Valneva SE (NASDAQ:VALN – Get Rating)'s share price gapped down before the market opened on Friday . The stock had previously closed at $14.04, but opened at $13.37. Valneva shares last traded at $13.40, with a volume of 102 shares.

Analyst Ratings Changes

VALN has been the subject of several recent analyst reports. The Goldman Sachs Group downgraded Valneva from a "buy" rating to a "neutral" rating in a research note on Friday, September 23rd. HC Wainwright reduced their price target on Valneva from $27.00 to $25.00 in a report on Monday, December 5th.

Valneva Price Performance

The company has a quick ratio of 1.02, a current ratio of 1.27 and a debt-to-equity ratio of 0.57. The business's 50 day moving average is $13.71 and its 200-day moving average is $16.29.

Institutional Investors Weigh In On Valneva

A number of institutional investors have recently made changes to their positions in the company. General American Investors Co. Inc. bought a new position in Valneva during the third quarter worth $3,768,000. Bank of America Corp DE bought a new position in shares of Valneva in the 1st quarter worth about $858,000. Jane Street Group LLC boosted its holdings in shares of Valneva by 85.9% in the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock valued at $569,000 after buying an additional 7,664 shares during the period. Finally, UBS Group AG bought a new stake in shares of Valneva during the 2nd quarter valued at about $31,000. 15.83% of the stock is currently owned by institutional investors.

Valneva Company Profile

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.

Recommended Stories

• Get a free copy of the StockNews.com research report on Valneva (VALN)
• MarketBeat: Week in Review 01/02-01/06
• Why is the CrowdStrike Stock Price Struggling?
• Four Undervalued Healthcare Stocks for 2023
• WWE Stock: Vince McMahon Wants Back In The Show
• NVIDIA Is Bottoming But Don't Buy It Just Yet

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.